Jade Biosciences, Inc. (JBIO) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-1.36x
Jade Biosciences, Inc. (JBIO) has a Cash Flow-to-Debt Ratio of -1.36x as of June 2026, meaning its operating cash flow of $-43.66 Million could theoretically repay -1% of its total liabilities ($32.20 Million) in one year. See Jade Biosciences, Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.36x
Operating CF / Total Liabilities
Operating Cash Flow
$-43.66 Million
USD
Total Liabilities
$32.20 Million
USD
Data as of
Jun 2026
Most recent filing
Jade Biosciences, Inc. Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Jade Biosciences, Inc. across 6 annual periods. For the full cash flow conversion analysis, see Jade Biosciences, Inc. (JBIO) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Jade Biosciences, Inc. (2020–2025)
Year-by-year debt coverage analysis for Jade Biosciences, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.49x | $-94.69 Million | $17.26 Million | ▲ +70.0% |
| 2024 | -18.26x | $-71.20 Million | $3.90 Million | ▼ -477.8% |
| 2023 | -3.16x | $-56.78 Million | $17.96 Million | ▲ +30.9% |
| 2022 | -4.57x | $-39.12 Million | $8.56 Million | ▲ +50.9% |
| 2021 | -9.30x | $-27.40 Million | $2.94 Million | ▼ -110.0% |
| 2020 | -4.43x | $-7.86 Million | $1.77 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.